Curriculum Vitae

Personal information

Anya Staal

Work experience

1. Employer: Federal Institute for Drugs and Medical Devices (BfArM)
   - Start date: 032020
   - End date:
   - Position: Non_clinical Assessor, Oncology / Endocrinology
   - Activities:

   _ Assessment of pharmacology and toxicology of oncologic and endocrinologic drugs

   - Country: Germany
2. Employer: Institute of Pharmacy, University of Bonn
   - Start date: 122016
   - End date: 022020
   - Position: Junior research group leader
   - Activities:

   _ Research on tumour cell resistance to anticancer drugs (resistance biomarkers, drug transport, cellular signaling)
   _ Editorial Board and reviewer activities
   _ Academic teaching, Pharmacy study andM.Sc. “Drug Research”

   - Country: Germany
3. Employer: Institute of Pharmacy, University of Bonn
   - Start date: 022008
   - End date: 112016
   - Position: Postdoctoral Fellow
   - Activities:

   _ Research on platinum drug resistance
   _ Academic teaching, Pharmacy study

   - Country: Germany
4. Employer: Institute of Pharmacy, University of Bonn
   - Start date: 032006
   - End date: 012008
   - Position: Postdoctoral Fellow of the Alexander_von_Humboldt Foundation
   - Activities:

   _ Project on cellular transport of platinum drugs

   - Country: Germany
5. Employer: Leiden University
   - Start date: 022002
   - End date: 022006
   - Position: PhD student
   - Activities:

   _ Research on cellular distribution of platinum anticancer complexes

   - Country: Netherlands

Education and training

1. Subject: University of Bonn
   - Start date: 092018
   - End date: 092020
   - Qualification: Master Drug Regulatory Affairs (MDRA)
   - Organisation:
   - Country: Germany
2. Subject: Leiden University
   - Start date: 022002
   - End date: 022006
   - Qualification: PhD in Medicinal Chemistry
   - Organisation:
   - Country: Netherlands
3. Subject: Leiden University
   - Start date: 062000
   - End date: 082001
   - Qualification: M.Sc. in Chemistry
   - Organisation:
   - Country: Netherlands
4. Subject: Taras Shevchenko National University of Kyiv
   - Start date: 091996
   - End date: 052000

- Qualification: B.Sc. in Chemistry
- Organisation:
- Country:

Additional information

Publications

* all under maiden name Kalayda G.V. Barakat, A.K.; Scholl, C.; Steffens, M.; Brandenburg, K.; Ising, M.; Lucae, S.; Holsboer, F.; Laje, G.; Kalayda, G.V.; Jaehde, U.; Stingl, J.C. Citalopram_induced pathways regulation and tentative treatment_outcome_predicting biomarkers in lymphoblastoid cell lines from depression patients. Transl. Psychiatry, 2020, 10, 1, 210. Möltgen, S.; Piumatti, E.; Massafra, G.M.; Metzger, S.; Jaehde, U.; Kalayda, G.V. Cisplatin Protein Binding Partners and Their Relevance for Platinum Drug Sensitivity. Cells, 2020, 9, 6, 1322. Dilruba, S.; Grondana, A; Schiedel, A.C.; Ueno, N.T.; Bartholomeusz, C.; Cinatl jr., J.; McLaughlin, K._M.; Wass, M.N.; Michaelis, M.; Kalayda, G.V. Non_phosphorylatable PEA_15 sensitises SKOV_3 ovarian cancer cells to cisplatin. Cells, 2020, 9, 2, 515. Kotz, S.; Kullmann, M.; Kalayda, G.V.; Dyballa_Rukes, N.; Jaehde, U.; Metzger, S. Optimized two_dimensional gel electrophoresis in an alkaline pH range improves the identification of intracellular CFDA_cisplatin_protein adducts in ovarian cancer cells. Electrophoresis, 2018, 39, 12, 1488_1496. Sarin, N.; Engel, F.; Rothweiler, F.; Cinatl jr., J.; Michaelis, M.; Frötschl, R.; Fröhlich, H.; Kalayda, G.V. Key players of cisplatin resistance: towards a systems pharmacology approach. Int. J. Mol. Sci., 2018, 19, 3, 767. Buß, I.; Hamacher, A.; Sarin, N.; Kassack, M.U.; Kalayda, G.V. Relevance of copper transporter 1 and organic cation transporters 1_3 for oxaliplatin uptake and drug resistance in colorectal cancer cells. Metallomics, 2018, 10, 414_425. Schneider, V.; Chaib, S.; Spanier, C.; Knapp, M.; Moscvin, V.; Scordovillo, L.; Ewertz, A.; Jaehde, U.; Kalayda, G.V. Transporter_Mediated Interaction Between Platinum Drugs and Sorafenib at the Cellular Level. AAPS J., 2018, 20, 9. Kalayda, G.V.; Kullmann, M.; Galanski, M.; Gollos, S. A fluorescent oxaliplatin analogue for live_cell imaging of oxaliplatin in cancer cells. J. Biol. Inorg. Chem., 2017, 22, 8, 1295_1304. Sarin, N., Engel, F.; Kalayda, G.V.; Mannewitz, M.; Cinatl Jr., J.; Rothweiler, F.; Michaelis, M.; Saafan, H.; Ritter, C.A.; Jaehde, U.; Frötschl, R. Cisplatin resistance in non_small cell lung cancer cells is associated with an abrogation of cisplatin_induced G2/M cell cycle arrest. PLoS One, 2017, 12, 7, e0181081. Sarin, N.; Engel, F.; Kalayda, G.V.; Frötschl, R.; Cinatl, J. Jr.; Rothweiler, F.; Michaelis, M.; Fröhlich, H.; Jaehde, U. Knowledge_based approach to identify key determinants of cisplatin sensitivity. Int. J. Clin. Pharmacol. Ther., 2017, 55, 8, 686_689. Dilruba, S.; Kalayda, G.V. Platinum_based drugs: past, present and future. Cancer Chemother. Pharmacol., 2016, 77, 1103_1124. Bosman, I.; Kalayda, G.V. Platinum complexes. In Encyclopedia of Cancer; Schwab, M., Ed.; Springer, 2016. Kullmann, M.; Kalayda, G.V.; Hellwig, M.; Kotz, S.; Hilger, R.A.; Metzger, S.; Jaehde, U. Assessing the contribution of the two protein disulfide isomerases PDIA1 and PDIA3 to cisplatin resistance. J. Inorg. Biochem., 2015, 153, 247_252. Kotz, S.; Kullmann, M.; Crone, B., Kalayda, G.V.; Jaehde, U.; Metzger, S. Combination of two_dimensional gel electrophoresis and a fluorescent carboxyfluorescein diacetate labeled cisplatin analogue allows the identification of intracellular cisplatin_protein adducts. Electrophoresis, 2015, 36, 21, 2811_2819. Dilruba, S.; Michaelis, M.; Cinatl jr., J.; Kalayda, G.V. Relevance of subcellular localisation of extracellular signal regulated kinase 1/2 (ERK1/2) for cisplatin resistance. Int. J. Clin. Pharmacol. Ther., 2015, 53, 12, 1041_1045. Kullmann, M.; Kotz, S.; Hellwig, M.; Kalayda, G.V.; Metzger, S.; Jaehde, U. GRP78 knockdown does not affect cytotoxicity of cisplatin in ovarian cancer cells. Int. J. Clin. Pharmacol. Ther., 2015, 53, 12, 1038_1040. Zabel, R.; Kullmann, M.; Kalayda, G.V.; Jaehde, U.; Weber, G. Optimized sample preparation strategy for the analysis of low molecular mass adducts of a fluorescent cisplatin analogue in cancer cell lines by CE_dual_LIF. Electrophoresis, 2015, 36, 4, 509_517. Mader, R.M.; Foerster, S.; Sarin, N.; Michaelis, M.; Cinatl, J. jr.; Kloft, C.; Fröhlich, H.; Engel, F.; Kalayda, G.V.; Jäger, W.; Frötschl, R.; Jaehde, U.; Ritter, C.A. NSCLC cells adapted to EGFR inhibition accumulate EGFR interacting proteins and down_regulate microRNA related to epithelial_mesenchymal transition. Int. J. Clin. Pharmacol. Ther., 2014, 52, 92_94. Kalayda, G.V.; Michaelis, M.; Cinatl, J. jr.; Mader, R.M.; Fröhlich, H.; Sarin, N.; Melin, J.; Engel, F.; Jäger, W.; Frötschl, R.; Jaehde, U.; Kloft, C.; Ritter, C.A. A systems pharmacology approach to improve drug therapy in NSCLC: establishing a CESAR network. Int. J. Clin. Pharmacol. Ther., 2014, 52, 89_91. Schneider, V.; Krieger, M.L.; Bendas, G.; Jaehde, U.; Kalayda, G.V. Contribution of intracellular ATP to cisplatin resistance of tumor cells. J. Biol. Inorg. Chem., 2013, 18, 165_174. Kalayda, G.V.; Wagner, C.H.; Jaehde, U. Relevance of copper transporter 1 for cisplatin resistance in human ovarian carcinoma cells. J. Inorg. Biochem., 2012, 116, 1_10. Buß, I.; Kalayda, G.V.; Lindauer, A.; Reithofer, M.R.; Galanski, M.; Keppler, B.K.; Jaehde, U. Effect of reactivity on cellular accumulation and cytotoxicity of oxaliplatin analogues. J. Biol. Inorg. Chem., 2012, 17, 699_708. Besançon, O.G.; Tytgat, G.A.; Meinsma, R.; Leen, R.; Hoebink, J.; Kalayda, G.V.; Jaehde, U.; Caron, H.N.; van Kuilenburg, A.B. Synergistic interaction between cisplatin and gemcitabine in neuroblastoma cell lines and multicellular tumor spheroids. Cancer Lett., 2012, 319, 23_30. Buß, I.; Garmann, D.; Galanski, M.; Weber, G.; Kalayda, G.V.; Keppler, B.K.; Jaehde, U. Enhancing lipophilicity as a strategy to overcome resistance against platinum complexes? J. Inorg. Biochem., 2011, 105, 709_717. Schneider, V.; Kalayda, G.V.; Krieger, M.L.; Bendas, G.; Jaehde, U. Intracellular ATP depletion leads to reduced platinum accumulation in ovarian cancer cells. Int. J. Clin. Pharmacol. Ther., 2010, 48, 456_458. Mohn, C.; Kalayda, G.V.; Häcker, H._G.; Gütschow, M.; Metzger, S.; Jaehde, U. Contribution of glutathione and MRP_mediated efflux to intracellular oxaliplatin accumulation. Int. J. Clin. Pharmacol. Ther., 2010, 48, 445_447. Kalayda, G.V.; Jaehde, U. Altered localization of transport proteins associated with cisplatin resistance. In Platinum and Other Heavy Metal Compounds in Cancer Chemotherapy: Molecular Mechanisms and Clinical Applications; Bonetti, A., Howell, S. B., Leone, R., Muggia, F., Eds.; Humana Press, 2009. Marques_Gallego, P.; Contaldi, S.; den Dulk, H.; Monari, M.; Brouwer, J.; Jaehde, U.; Kalayda, G.V.; Reedijk, J. Relevance of the leaving group for antitumor activity of new platinum(II) compounds containing anthracene derivatives as a carrier ligand. J. Inorg. Biochem., 2009, 103, 12, 1602_1608. Marques_Gallego, P.; Kalayda, G.V.; Jaehde, U.; den Dulk, H.; Brouwer, J.; Reedijk, J. Cellular accumulation and DNA platination of two new platinum(II) anticancer compounds based on anthracene derivatives as carrier ligands. J. Inorg. Biochem., 2009, 103, 5, 791_796. Buß, I.; Kalayda, G.V.; Marques_Gallego, P.; Reedijk, J.; Jaehde, U. Influence of the hOCT2 inhibitor cimetidine on the cellular accumulation and cytotoxicity of oxaliplatin. Int. J. Clin. Pharmacol. Ther., 2009, 47, 51_54. Kalayda, G.V.; Wagner, C.H.; Buß, I.; Reedijk, J.; Jaehde, U. Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells. BMC Cancer, 2008, 8, 175. Garmann, D.; Warnecke, A.; Kalayda, G.V.; Kratz, F.; Jaehde, U. Cellular accumulation and cytotoxicity of macromolecular platinum complexes in cisplatin_resistant tumor cells. J. Control. Release, 2008, 131, 100_106. Kalayda, G.V.; Fakih, S.; Bertram, H.; Ludwig, T.; Oberleithner, H.; Krebs, B.; Reedijk, J. Structure_toxicity relationships for different types of dinuclear platinum complexes. J. Inorg. Biochem., 2006, 100, 8, 1332_1338. Kalayda, G.V.; Zhang, G.; Abraham, T.; Tanke, H.J.; Reedijk, J. Application of fluorescence microscopy for investigation of cellular distribution of dinuclear platinum anticancer drugs. J. Med. Chem., 2005, 48, 5191_5202. Kalayda, G.V.; Jansen, B.A.J.; Wielaard, P.; Tanke, H.J.; Reedijk, J. Dinuclear platinum anticancer complexes with fluorescent N,N′_bis(aminoalkyl)_1,4_diaminoanthraquinones: cellular processing in two cisplatin resistant cell lines reflects the differences in their resistance profiles. J. Biol. Inorg. Chemistry, 2005, 10, 305_315. Meistermann, I.; Kalayda, G.V.; Hotze, A.C.G.; Reedijk, J. Preparation of a new Ruthenium(II) building block for the synthesis of mixed_metal complexes. Tetrahedron Lett., 2004, 45, 2593_2596. Jansen, B.A.J.; Wielaard, P.; Kalayda, G.V.; Ferrari, M.; Molenaar, C.; Tanke, H.J.; Brouwer, J.; Reedijk, J. Dinuclear platinum complexes with N,N′_bis(aminoalkyl)_1,4_diaminoanthraquinones as linking ligands. Part I. Synthesis, cytotoxicity, and cellular studies in A2780 human ovarian carcinoma cells. J. Biol. Inorg. Chem., 2004, 9, 4, 403_413. Kalayda, G.V.; Jansen, B.A.J.; Molenaar, C.; Wielaard, P.; Tanke, H.J.; Reedijk, J. Dinuclear platinum complexes with N,N′_bis(aminoalkyl)_1,4_diaminoanthraquinones as linking ligands. Part II. Cellular processing in A2780 cisplatin_resistant human ovarian carcinoma cells. New insights in the mechanism of resistance. J. Biol. Inorg. Chem., 2004, 9, 4, 414_422. Kalayda, G.V.; Komeda, S.; Ikeda, K.; Sato, T.; Chikuma, M.; Reedijk, J. Synthesis, structure and biological activity of new azine_bridged dinuclear platinum(II) complexes _ a new class of anticancer compounds. Eur. J. Inorg. Chem., 2003, 24, 4347_4355. Herrera, A.M.; Kalayda, G.V.; Disch, J.S.; Wikstrom, R.P.; Korendovych, I.V.; Staples, R.J.; Campana, C.F.; Nazarenko, A.Y.; Haas, T.E.; Rybak_Akimova, E.V. Reactions at the azomethine C=N bonds in the nickel(II) and copper(II) complexes of pyridine_containing Schiffbase macrocyclic ligands. J. Chem. Soc., Dalton Trans., 2003, 23, 4482_4492. Komeda, S.; Kalayda, G.V.; Lutz, M.; Spek, A.L.; Yamanaka, Y.; Sato, T.; Chikuma, M.; Reedijk, J. New isomeric azine_bridged dinuclear platinum(II) complexes circumvent cross_resistance to cisplatin. J. Med. Chem, 2003, 46, 7, 1210_1219.

Projects	
Memberships	Member of the German Pharmaceutical Society (DPhG) Member of Central European Society for Anticancer Drug Research Editorial Board Member, Cancer Drug Resistance
Other Relevant Information	